| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010943745 |
| P356 | DOI | 10.1007/S00213-011-2315-3 |
| P932 | PMC publication ID | 4009981 |
| P698 | PubMed publication ID | 21537940 |
| P2093 | author name string | L Elliot Hong | |
| Robert P McMahon | |||
| Gunvant K Thaker | |||
| Ikwunga Wonodi | |||
| Judy Liu | |||
| Helene Adami | |||
| Hirekatur V Gopinath | |||
| Robert Allen-Emerson | |||
| P2860 | cites work | Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. | Q37719729 |
| The current status of the dopamine hypothesis of schizophrenia | Q39577491 | ||
| Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia | Q41620234 | ||
| Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions | Q43605913 | ||
| Allopurinol augmentation for poorly responsive schizophrenia | Q43679598 | ||
| Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine a(1) receptors | Q44138965 | ||
| Up-regulation of striatal adenosine A(2A) receptors in schizophrenia | Q44360359 | ||
| Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation | Q45138309 | ||
| Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. | Q45252687 | ||
| Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group | Q47771537 | ||
| A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. | Q48658263 | ||
| The Maryland Psychiatric Research Center scale and the characterization of involuntary movements | Q48725859 | ||
| Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum | Q48966123 | ||
| The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. | Q51985129 | ||
| Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial | Q60638962 | ||
| Dipyridamole attenuates the development of iminodipropionitrile-induced dyskinetic abnormalities in rats | Q71726094 | ||
| Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia | Q71933595 | ||
| Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia | Q72649876 | ||
| Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions | Q73884115 | ||
| Mapping of a human A2a adenosine receptor (ADORA2) to chromosome 22 | Q28244302 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes | Q28292838 | ||
| Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice | Q28340819 | ||
| Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy | Q30457808 | ||
| The effects of galantamine on psychopathology in chronic stable schizophrenia | Q33724801 | ||
| Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. | Q34011836 | ||
| Caffeine as a psychomotor stimulant: mechanism of action. | Q34314690 | ||
| Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs | Q34338202 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP) | Q34536971 | ||
| A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. | Q34728117 | ||
| The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment | Q35619021 | ||
| Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience | Q36172464 | ||
| Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications | Q36437613 | ||
| Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia | Q36809091 | ||
| Adenosine A(2A) receptors in Parkinson's disease treatment | Q36973390 | ||
| P433 | issue | 2 | |
| P921 | main subject | schizophrenia | Q41112 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 341-345 | |
| P577 | publication date | 2011-05-03 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling | |
| P478 | volume | 218 |
Search more.